The Cystic Fibrosis Center at CWRU conducts translational research, with preclinical and clinical research projects that utilize a number of coe facilities. This application requests funds for 5 biomedical research cores, an administrative component and 2 pilot and feasibility projects. The cores include an internationally utilized 1. Mouse Models Core that provides mice and relevant assays for in vivo studies;2) a Bioanalyte Core to measure a range of molecules routinely analyzed by investigators;3) a Clinical Studies Core to facilitate clinical research projects;4) a Biostatistics and Bioinformatics Core to accommodate the evolving and increasing statistical and computations needs of Center investigators, and 5) a Rodent Imaging Core to provide in vivo monitoring for various studies. The purpose of these cores, administrative and feasibility components are:1) to provide researchers with state of the art core facilities and necessary reagents to optimize and improve the throughput of their CF-related research while maintaining or improving the quality of studies by providing centralized services. This goal is realized by the Biomedical Research Cores. 2) to provide a centralized resource for coordinating activities of the CF Center, including allocation o pilot and feasibility awards, an enrichment program and interaction with other institutional resources (other cores, CTSA, etc.). This goal will be addressed by the Administrative Component and executive committee. 3) to bring research discoveries to the clinic. Our CF Center has a long track record implementing this goal and proposes to continue to do so, capitalizing on new and exciting developments from within our Center as well as through collaborations with outside investigators. This goal is facilitated by the Biomedical Research Cores, with specific emphasis on the Clinical Studies Core. 4) to provide training and mentoring in CF-related research for students and fellows embarking on research projects, as well as investigators pursuing new avenues of research. This goal is also a function of the Biomedical Research Cores.
Core facilities and infrastructural support have expedited CF research and reduced costs while accelerating the processes of moving science to therapy. The cores described in this application are all relevant to improving our understanding of cystic fibrosis and using that information to develop and improve therapies.
|Dasenbrook, Elliott C; Konstan, Michael W; VanDevanter, Donald R (2015) Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J Cyst Fibros 14:370-5|
|Than, B L N; Goos, J A C M; Sarver, A L et al. (2014) The role of KCNQ1 in mouse and human gastrointestinal cancers. Oncogene 33:3861-8|
|Xu, Weiling; Janocha, Allison J; Leahy, Rachel A et al. (2014) A novel method for pulmonary research: assessment of bioenergetic function at the air-liquid interface. Redox Biol 2:513-9|
|Boyle, Michael P; Bell, Scott C; Konstan, Michael W et al. (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2:527-38|
|Doring, Gerd; Bragonzi, Alessandra; Paroni, Moira et al. (2014) BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 13:156-63|
|Spilker, Theodore; Leber, Amy L; Marcon, Mario J et al. (2014) A simplified sequence-based identification scheme for Bordetella reveals several putative novel species. J Clin Microbiol 52:674-7|
|Zaman, Khalequz; Bennett, Deric; Fraser-Butler, Maya et al. (2014) S-Nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface. Biochem Biophys Res Commun 443:1257-62|
|VanDevanter, Donald R; Pasta, David J; Konstan, Michael W (2014) Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012. J Pediatr 165:1091-1097.e2|
|Caretti, Anna; Bragonzi, Alessandra; Facchini, Marcella et al. (2014) Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis. Biochim Biophys Acta 1840:586-94|
|Kerem, Eitan; Konstan, Michael W; De Boeck, Kris et al. (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2:539-47|
Showing the most recent 10 out of 274 publications